Purpose: The aim of this study was to evaluate the activity and safety of epirubicin (EPI), oxaliplatin (l-OHP) and 5fluorouracil (5FU) (EOF) followed by docetaxel (D), l-OHP and 5FU (DOF) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Methods: Forty-five patients were enrolled: 26 gastric and 19 GEJ cancer. Median age was 69 years (range 34-83); ECOG performance status was 0-1 in 37 patients. Treatment consisted of EPI 50 mg/m2 combined with l-OHP 130 mg/m2 on day 1 and continuous infusion 5FU 750 mg/m2 days 1-5 (EOF), every 3 weeks for a maximum of 4 cycles. After EOF completion, patients received D 70 mg/m2 combined with l-OHP 130 mg/m2 on day 1 and continuous infusion 5FU 750 mg/m2 days 1-5 (DOF), every 3 weeks for a maximum of 4 cycles. Results: After sequential EOF/DOF, the overall response rate was 51.1 % (95 % CI 35.7-66.2 %) and 93.3 % of patients were progression free 6 months after the onset of chemotherapy. The median progression-free survival was 9.5 months (95 % CI 8.0-11.9 months), and the median overall survival was 15.8 months (95 % CI 13.6-18.9 months). Grade 3 neutropenia was observed in 15 patients (33.3 %) after sequential EOF/DOF. Conclusions: The sequential treatment EOF/DOF is feasible in well-selected patients with advanced gastric or GEJ cancer and shows encouraging survival results

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience / PETRIOLI, ROBERTO; Francini, Edoardo; ROVIELLO, FRANCO; MARRELLI, DANIELE; FIASCHI, ANNA IDA; LAERA, LETIZIA; ROSSI, GIULIA; Bianco, V; Brozzetti, S; ROVIELLO, GIANDOMENICO. - In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. - ISSN 0344-5704. - STAMPA. - 75:(2015), pp. 941-947. [10.1007/s00280-015-2715-x]

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience

Francini, Edoardo;LAERA, LETIZIA;ROVIELLO, GIANDOMENICO
2015

Abstract

Purpose: The aim of this study was to evaluate the activity and safety of epirubicin (EPI), oxaliplatin (l-OHP) and 5fluorouracil (5FU) (EOF) followed by docetaxel (D), l-OHP and 5FU (DOF) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Methods: Forty-five patients were enrolled: 26 gastric and 19 GEJ cancer. Median age was 69 years (range 34-83); ECOG performance status was 0-1 in 37 patients. Treatment consisted of EPI 50 mg/m2 combined with l-OHP 130 mg/m2 on day 1 and continuous infusion 5FU 750 mg/m2 days 1-5 (EOF), every 3 weeks for a maximum of 4 cycles. After EOF completion, patients received D 70 mg/m2 combined with l-OHP 130 mg/m2 on day 1 and continuous infusion 5FU 750 mg/m2 days 1-5 (DOF), every 3 weeks for a maximum of 4 cycles. Results: After sequential EOF/DOF, the overall response rate was 51.1 % (95 % CI 35.7-66.2 %) and 93.3 % of patients were progression free 6 months after the onset of chemotherapy. The median progression-free survival was 9.5 months (95 % CI 8.0-11.9 months), and the median overall survival was 15.8 months (95 % CI 13.6-18.9 months). Grade 3 neutropenia was observed in 15 patients (33.3 %) after sequential EOF/DOF. Conclusions: The sequential treatment EOF/DOF is feasible in well-selected patients with advanced gastric or GEJ cancer and shows encouraging survival results
2015
75
941
947
Goal 3: Good health and well-being for people
PETRIOLI, ROBERTO; Francini, Edoardo; ROVIELLO, FRANCO; MARRELLI, DANIELE; FIASCHI, ANNA IDA; LAERA, LETIZIA; ROSSI, GIULIA; Bianco, V; Brozzetti, S; ...espandi
File in questo prodotto:
File Dimensione Formato  
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF).pdf

Accesso chiuso

Dimensione 415.54 kB
Formato Adobe PDF
415.54 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1156801
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact